BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ubaldi M, Cannella N, Ciccocioppo R. Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. Prog Brain Res 2016;224:251-84. [PMID: 26822362 DOI: 10.1016/bs.pbr.2015.07.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Chan YL, Saad S, Machaalani R, Oliver BG, Vissel B, Pollock C, Jones NM, Chen H. Maternal Cigarette Smoke Exposure Worsens Neurological Outcomes in Adolescent Offspring with Hypoxic-Ischemic Injury. Front Mol Neurosci 2017;10:306. [PMID: 29018327 DOI: 10.3389/fnmol.2017.00306] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
2 Kubota M, Seki C, Kimura Y, Takahata K, Shimada H, Takado Y, Matsuoka K, Tagai K, Sano Y, Yamamoto Y, Okada M, Kikuchi T, Ichise M, Kawamura K, Zhang MR, Higuchi M. A first-in-human study of 11C-MTP38, a novel PET ligand for phosphodiesterase 7. Eur J Nucl Med Mol Imaging 2021;48:2846-55. [PMID: 33566152 DOI: 10.1007/s00259-021-05235-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Massaly N, Morón JA. Pain And Opioid Systems, Implications In The Opioid Epidemic. Curr Opin Behav Sci 2019;26:69-74. [PMID: 30984806 DOI: 10.1016/j.cobeha.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cannella N, Ubaldi M, Masi A, Bramucci M, Roberto M, Bifone A, Ciccocioppo R. Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. Neurosci Biobehav Rev 2019;103:384-98. [PMID: 31112713 DOI: 10.1016/j.neubiorev.2019.05.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Witkin JM, Wallace TL, Martin WJ. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). In: Ko M, Caló G, editors. The Nociceptin/Orphanin FQ Peptide Receptor. Cham: Springer International Publishing; 2019. pp. 399-415. [DOI: 10.1007/164_2018_186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Borruto AM, Stopponi S, Li H, Weiss F, Roberto M, Ciccocioppo R. Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation? Neuropharmacology 2021;186:108446. [PMID: 33476639 DOI: 10.1016/j.neuropharm.2020.108446] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]